Observational studyInternational urology and nephrology2025
Hepatitis C virus among hemodialysis patients: burden, risks, and prevention in resource-limited regions.
Observational study in International urology and nephrology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- High prevalence of seronegative occult hepatitis C in high-risk individuals.Iranian journal of microbiology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHepatitis C virus (HCV) poses a significant health risk to hemodialysis patients because of their increased susceptibility to infection, especially in resource-limited environments. HCV infection can result in severe complications such as liver failure and higher mortality rates. This study evaluated the prevalence of HCV infection among patients undergoing hemodialysis and identified critical risk factors to enhance targeted prevention strategies.
methodsA cross-sectional, observational study was conducted at Damascus Hospital and Surgical Kidney Hospital between 2017 and 2022 to assess HCV prevalence and associated risk factors in hemodialysis patients. Data included demographics, dialysis duration, dialysis route, history of blood transfusion, liver function test results, and anti-HCV antibody results. Statistical analyses were performed using chi-square tests, ANOVA, and t-tests.
resultsOf the 200 hemodialysis patients, 24% tested positive for HCV virus. Infection rates were significantly higher in patients with longer dialysis durations (p = 0.001), double-lumen catheter use (32.5% of the sample), and history of blood transfusions (20% of the sample). Patients who primarily underwent AV fistula dialysis showed comparatively lower infection risk. Additionally, demographic factors such as urban residency and older age were observed in a higher proportion of HCV-positive patients, although the difference was not statistically significant.
conclusionThis study highlighted a significant HCV burden among hemodialysis patients, with infection risk correlating with dialysis duration, blood transfusion history, and catheter type. These findings underscore the need for consistent infection control measures and targeted interventions to reduce HCV transmission and improve patient outcomes, especially in regions with limited healthcare resources.
Indexed as
Identifiers
40335857What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.